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Erythropoietin stimulates murine and human 
fibroblast growth factor-23, revealing novel roles for
bone and bone marrow 
Early stages of chronic kidney disease (CKD) are char-
acterized by development of progressive anemia1 as well
as concurrent marked elevation of the phosphaturic hor-
mone fibroblast growth factor 23 (FGF23).2 As kidney
function declines, FGF23 further increases and anemia
worsens, due to either inadequate production of renal
erythropoietin (EPO) or incidence of hypoferremia.
Moreover, in CKD, anemia and elevated FGF23 levels are
associated with left ventricular hypertrophy (LVH),3 CKD
progression,4 and mortality.2 Treatment of CKD-related
anemia involves iron repletion and erythropoietin (EPO)
administration. EPO is one of the most extensively used
medications in CKD, but its administration is associated
with increased risks of cardiovascular disease and mortal-
ity.5  Although FGF23 levels increase early in CKD, the
pathophysiological regulation of FGF23 is still not com-
pletely understood. Phosphate, 1,25-dihydroxyvitamin D
(1,25D), parathyroid hormone, and calcium affect FGF23
production; however, these factors are still within normal
ranges when bone and circulating FGF23 increase. Recent
studies demonstrate intriguing associations between
hypoxia, iron deficiency, and FGF23 upregulation.
Indeed, in the settings of normal and impaired6 kidney
function, iron deficiency potently increases bone Fgf23
expression. However, other anemia-related factors,
including EPO, could potentially contribute to elevated
FGF23 production. As both EPO therapy and FGF23 are
associated with adverse outcomes in CKD, we explored
the hypothesis that EPO is a previously unrecognized
regulator of this phosphaturic hormone. Collectively, our
pre-clinical findings suggest that modulating EPO expo-
sure in CKD patients may lower FGF23 and thereby
decrease its adverse effects.
To examine whether exogenous EPO stimulates FGF23
in vivo, wild-type C57BL/6 mice at 6-8 weeks of age were
injected with increasing doses of recombinant human
EPO (25-250 U/g of body weight). A 3-day regimen
induced a dose-dependent, 40-fold maximal increase in
whole bone Fgf23 mRNA expression (Figure 1A), paral-
leled by increased serum total FGF23 as measured with
an ELISA that detects both C-terminal FGF23 fragments
(‘cFGF23’) and bioactive intact FGF23 (‘iFGF23’) (Figure
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Figure 1. Erythropoietin (EPO) is a stimulator of FGF23.  (A) Injections of EPO (50-250 U/g/d of body weight) over a 3-day time course dose-dependently
increased serum cFGF23 as well as whole intact femur Fgf23 mRNA (*P<0.05, **P<0.01 vs. saline controls). (B) Serum iFGF23, measured with  the Quidel
rodent specific ELISA, was significantly elevated following EPO delivery (125 U/g/d body weight; ***P<0.001), (C) which correlated with a significant decrease
in serum phosphate (*P<0.05). Markers of EPO activity, including (D) spleen weight and (E) whole bone TfRc mRNA, were increased in EPO-injected mice (n=3-
8 mice at each time point; **P<0.01). (F) Serum cFGF23 levels progressively increased in 4 anemic patients treated with EPO, with a significant elevation over
baseline levels observed at the 12-24 hour (h) time points (P<0.05). (G) Serum iFGF23, measured with the Quidel human-specific ELISA, mirrored cFGF23, with
significant increases observed 12 and 18 h post injection. (H) After receiving EPO, serum hepcidin was significantly decreased in these subjects, indicative of
normal EPO function. (I) Jck and C57 mice were injected with either saline or 125 U/g EPO. EPO treatment increased iFGF23 in C57 and Jck mice, with Jck
iFGF23 concentrations significantly higher versus C57 mice; n=6 mice per group; **P<0.01 versus saline treatment of the same genotype, ǂǂP<0.01 versus C57
same treatment. (J) EPO treatment increased whole bone Fgf23 mRNA in C57 and in Jck mice (*P<0.02 and **P<0.01 compared to saline treatment of the
same genotype). (I) Jck and C57 mice were injected with either ferric carboxymaltose (FCM) alone or in combination with EPO (EPO+FCM) during the 3-day reg-
imen. FCM alone reduced serum iFGF23 in the Jck mice, whereas FCM+EPO increased iFGF23 in both genotypes, with higher iFGF23 concentrations observed
in the Jck mice compared to C57 (n=6 mice per group; *P<0.05 and **P<0.01 vs. saline treatment of the same genotype).
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1A). Compared to controls, three days of an intermediate
dose of 125 U/g/day  EPO doubled iFGF23 concentra-
tions (Figure 1B), with a parallel reduction in serum phos-
phate (Figure 1C). EPO stimulated erythropoiesis, as indi-
cated by increased spleen weight (Figure 1D) and whole
bone transferrin receptor-1 (TfRc) mRNA expression
(Figure 1E).
We next performed a study in which 4 human subjects
with anemia of unclear etiology but normal renal func-
tion received a subcutaneous dose of EPO. Serum was
sampled pre-injection and every six hours post-injection
for 48 hours (h) and then analyzed for cFGF23, iFGF23,
iron, hepcidin, and phosphate (Online Supplementary Table
S1). Despite variations in baseline ferritin levels among
the 4 patients, indicative of different iron and inflamma-
tory status, all subjects responded similarly to EPO
administration by increasing FGF23. Indeed, 12 h post-
EPO administration, cFGF23 was significantly increased
(P<0.05) (Figure 1F and Online Supplementary Figure S1);
iFGF23 paralleled this response (Figure 1G and Online
Supplementary Figure S1). There was little change in
serum phosphate over this short time course (Online
Supplementary Figure S2). As expected, EPO significantly
decreased hepcidin, which helped maintain serum iron
(Figure 1H and Online Supplementary Figure S3). 
Erythropoietin effects on FGF23 were also examined in
the juvenile cystic kidney (Jck) mouse, a model character-
ized by increased iFGF23 (Online Supplementary Figure
S4A) and progressive CKD.7 Reductions in red blood cell
count, hemoglobin and hematocrit were observed as
early as four weeks of age in Jck mice compared to nor-
mal C57BL/6 (C57) mice (Online Supplementary Table S2),
along with reduced serum iron and inappropriately low
EPO (Online Supplementary Figure S4B and C). In line with
the studies above, 6-week old mice were administered
EPO (125 U/g) which increased iFGF23 in both C57 and
Jck mice; however, Jck mice had higher iFGF23 (Figure
1I), which paralleled whole bone Fgf23 mRNA expres-
sion (Figure 1J). To rule out EPO-induced functional iron
deficiency, ferric carboxymaltose (FCM; 80 mg/kg) was
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Figure 2.  Marrow-derived FGF23 contributes to the response to erythropoietin (EPO). (A) Marrow ablation in wild-type mice using carboplatin (‘Carbo’) com-
pletely blocked the induction of ERFE in response to EPO (inset; ND: not detected). Although serum cFGF23 was induced in all groups treated with EPO, marrow
ablation reduced these levels by approximately 40%. (B) Fgf23 mRNA, normalized to Hprt, was induced in cortical bone flushed of marrow in all groups treated
with EPO (n=5-6; **P<0.01 vs. same pre-treatment + Saline; #P<0.05 and ##P<0.01 vs. water ablation control+same post-treatment). (C) A -5kb Fgf23 pro-
moter fragment responded positively to EPO treatment versus the promoter fragment alone or mock transfected ROS17/2.8 osteoblastic cells. 1,25D treatment
served as the positive control (n=3 replicates per treatment). (D) Flushed bone marrow RNA from mice treated with EPO showed a significant increase in Fgf23
and Erfe mRNA levels (normalized to Hprt) compared to flushed bone marrow from saline-injected mice (n=4 mice per group; **P<0.001). (E) Isolated bone
marrow cells were cultured ex vivo and treated with 100 U/mL of EPO for 4 h, showing a significant increase in Fgf23 mRNA expression (**P<0.01). (F) An
enriched population of Lineage− cells was isolated from flushed bone marrow using a hematopoietic progenitor separation kit. Treatment of wild-type C57 mice
with EPO resulted in a significant increase of Fgf23 mRNA expression compared to that of saline-treated mice (n=4 replicates, pools from at least 2 mice;
P<0.05). Col1a1 mRNA, a marker of osteoblasts, was significantly reduced in this enriched population compared to wild-type whole bone and wild-type cortical
bone flushed of marrow to show a lack of osteoblasts within this preparation (inset; *P<0.05 vs. whole bone and cortical bone). (G) Marrow from C57 control
mice injected with saline or EPO were stained and co-sorted with flow cytometry for LSK and CMP cell populations while the cortical bone was collagenase
digested. The sorted LSK cells significantly induced Fgf23 mRNA in response to EPO (n=4 pools from 2-3 mice; **P<0.01). Cortical digested cells also showed
a significant Fgf23 mRNA induction with EPO treatment (**P<0.01), whereas the CMP cells were at the limit of detection and remained significantly lower com-
pared to the LSK and cortical digested cells (ǂǂP<0.01 vs. LSK and cortical digests treated with EPO). Data represented as mean+standard error of mean (SEM).
(H) Our data demonstrate that EPO can induce FGF23 production in osteoblasts/osteocytes and hematopoietic progenitors, with excess FGF23 potentially lead-
ing to altered renal mineral metabolism and other pathogenic actions. 
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administered through tail vein injection either alone or
with EPO. While there was no measured change in serum
iron, whole bone Fgf23 mRNA and the EPO-responsive
erythroblast-derived hormone erythroferrone (Erfe)
mRNA were reduced with FCM treatment, in contrast to
increases with EPO+FCM. As controls, FCM and EPO
increased and reduced, respectively, liver hepcidin levels,
demonstrating appropriate changes in iron metabolism
with treatment (Online Supplementary Figure S5). Whereas
FCM alone reduced serum iFGF23 in the Jck mice,
EPO+FCM increased serum iFGF23 in both genotypes
(and again was significantly higher in the Jck mice com-
pared to C57), confirming iron-independent EPO stimu-
lation of FGF23 (Figure 1K). 
Erythropoietin is known to target marrow erythropoi-
etic precursors, so to assess the EPO-dependent contribu-
tion of these cells to FGF23 production, wild-type mice
were given a single dose of marrow ablative carboplatin
(2.5 mg/mouse)8 one day prior to 125 U/g/d EPO injec-
tions administered for three days, using saline as control.
Compared to mock ablation controls, in carboplatin pre-
treated mice, ERFE was undetectable (Figure 2A, inset)
confirming ablation, and serum cFGF23 showed around
40% reduced response (Figure 2A). However, there was
no difference in Fgf23 mRNA expression within the cor-
tical bone flushed of marrow  (Figure 2B), supporting the
hypothesis that a lack of marrow FGF23 production
decreased circulating levels, and that EPO had direct
effects on cortical FGF23-producing bone cells. These
data also support no direct role for  ERFE  during EPO
stimulation of FGF23. Interestingly, we found that iron
chelation with deferoxamine (DFO) increased EPO recep-
tor (EpoR) mRNA expression in the osteoblast-like cell
line UMR-106 (Online Supplementary Figure S6A), possibly
providing a mechanism for enhancing EPO-responsive-
ness in bone. Since we had previously found that DFO
independently stimulates Fgf23 transcription,9 ROS
osteoblast-like cells were co-transfected with a -5kb
mouse Fgf23 promoter-luciferase construct and the
human EPOR to mimic EpoR upregulation. Luciferase
activity was significantly enhanced after 24 h of treat-
ment with both 100 U/mL EPO and the positive control
1,25D (10-8M), compared to control treated cells (Figure
2C). Furthermore, EPO treatment of UMR-106 cells over-
expressing the EPOR elicited a significant increase in
Fgf23 mRNA expression, as well as increased phosphory-
lation of STAT5 and ERK1/2 (Online Supplementary Figure
S6B and C). 
The NCBI GEO gene array data set GSE7874 demon-
strated that human peripheral blood CD34+ hematopoiet-
ic stem cells cultured with EPO have an 8-fold increase in
FGF23 mRNA expression. Accordingly, in mice treated
with EPO, Fgf23mRNA expression was increased 11-fold
in marrow flushed from femurs (Figure 2D). As expected,
EPO also increased marrow Erfe expression (Figure 2D).
In addition, isolated bone marrow cells treated ex vivo
with 100 U/mL EPO increased Fgf23 mRNA after 4 h
(Figure 2E). To determine if other EPO-responsive tissues
could express Fgf23, spleen RNA was isolated in parallel
with bone and flushed marrow. Fgf23 mRNA expression
was significantly elevated in spleen, further supporting
an effect of EPO on FGF23 in erythroid precursor cells
(Online Supplementary Figure S7). To begin to identify the
marrow cell populations capable of expressing FGF23,
hematopoietic progenitor cells were collected from the
marrow of EPO- and saline-injected mice using negative
selection to enrich Lineage– cells,10 as Fgf23 mRNA was
previously found in Ter119+ erythrocytes.11 Fgf23 mRNA
was detectable in control cells, but was potently induced
more than 70-fold with EPO treatment (Figure 2F). Flow
cytometry sorting of Lineage– c-kit+ Sca1+ (LSK) cells from
EPO-injected mice showed a significant induction of
Fgf23 mRNA (>40-fold vs. saline-injected controls)
(Figure 2G). Collagenase digested bone showed 5-fold
higher levels of Fgf23 mRNA compared to LSK at base-
line, which significantly increased in response to EPO
(Figure 2G). The common myeloid progenitor (CMP) cell
population was negative for Fgf23 mRNA and rose only
to the limit of detection with EPO treatment, thus
remaining far lower than both LSK and the cortical
digests from EPO-treated mice (Figure 2G). In summary,
our results strongly support a new functional model
whereby EPO directly affects FGF23 production in
hematopoietic progenitor cell subsets and cortical bone,
revealing novel roles for these sites in controlling
crossover iron and phosphate homeostasis (Figure 2H).
FGF23 regulation is determined by an interplay of sys-
temic and local factors that now extends beyond the
‘typical’ feedback loops associated with phosphate and
1,25D homeostasis.  Notably, iron deficiency stimulates
FGF23 production,6,9,12 and most CKD patients develop
anemia with iron deficiency or iron restriction.1  However,
studies of the effects of various intravenous iron formula-
tions on cFGF23 and/or iFGF23 in CKD patients have
been inconclusive. In the light of our results demonstrat-
ing EPO-mediated stimulation of FGF23, these previous
studies may have been confounded by the interactive
effects of endogenous or exogenous EPO on FGF23 pro-
duction and stabilization. In addition to its well-estab-
lished role in erythropoiesis, EPO can directly activate
transcription of osteogenic genes in human cell lines;13
thus, EPO may influence FGF23 expression in osteoblas-
tic cells as well as in hematopoietic cells. Clinical trials
with CKD patients have shown that higher EPO doses
are associated with adverse cardiovascular effects,5
although the mechanism is not well understood. Elevated
FGF23 levels are also associated with poor patient out-
comes,2-4 with a plausible mechanism suggested by ani-
mal models linking high FGF23 levels to
cardiomyopathy.3 Expanded studies in patient cohorts
will be necessary to derive the full overlap of specific
interactions between EPO and FGF23. Therefore, our col-
lective findings may have important clinical implications
for patients, supporting an exploration of current CKD-
associated anemia and CKD-mineral bone disorder treat-
ment paradigms to optimize the therapeutic use of EPO.
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